Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.

Ruff MW, Buckner JC, Johnson DR, van den Bent MJ, Geurts M.

Neurooncol Pract. 2019 Jan;6(1):17-21. doi: 10.1093/nop/npy044. Epub 2018 Nov 3. Review.

PMID:
31386006
2.

Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?

Lassman AB.

CNS Oncol. 2015;4(5):341-6. doi: 10.2217/cns.15.36. Epub 2015 Nov 6. Review.

3.

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B.

Ann Oncol. 2003 Apr;14(4):599-602.

PMID:
12649108
4.

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.

Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S.

Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14.

5.

Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.

Roth P, Wick W, Weller M.

Curr Treat Options Oncol. 2013 Dec;14(4):505-13. doi: 10.1007/s11864-013-0251-7.

6.

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, et al.

J Clin Oncol. 1994 Oct;12(10):2013-21.

PMID:
7931469
7.

Adults with newly diagnosed high-grade gliomas.

Croteau D, Mikkelsen T.

Curr Treat Options Oncol. 2001 Dec;2(6):507-15. Review.

PMID:
12057096
8.
9.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.

J Clin Oncol. 2006 Jun 20;24(18):2715-22.

PMID:
16782911
10.

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.

J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.

PMID:
23071237
11.

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.

Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R.

J Clin Oncol. 2003 Jan 15;21(2):251-5.

PMID:
12525516
12.

Anaplastic glioma.

Paleologos NA, Merrell RT.

Curr Treat Options Neurol. 2012 Aug;14(4):381-90. doi: 10.1007/s11940-012-0177-6.

PMID:
22665140
13.

Low-grade and anaplastic oligodendroglioma.

Van Den Bent MJ, Bromberg JE, Buckner J.

Handb Clin Neurol. 2016;134:361-80. doi: 10.1016/B978-0-12-802997-8.00022-0. Review.

PMID:
26948366
14.

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP.

J Clin Oncol. 2012 Sep 1;30(25):3065-70. doi: 10.1200/JCO.2011.35.8598. Epub 2012 Jul 30.

15.

Initial chemotherapy in gliomatosis cerebri.

Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY; ANOCEF group.

Neurology. 2004 Jul 27;63(2):270-5.

PMID:
15277619
16.
17.
18.

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.

Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):58-66.

PMID:
12007942
19.

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W.

Neurology. 1998 Oct;51(4):1140-5.

PMID:
9781544
20.

A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.

Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE.

J Neurooncol. 2008 Sep;89(2):187-93. doi: 10.1007/s11060-008-9603-8. Epub 2008 May 6.

PMID:
18458821

Supplemental Content

Support Center